Streetwise Reports' Article Archives — November 2022 back to current month (29)
Target Price Boosted on Canadian Pharma Co. (11/30/2022)
This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.
Biopharma Co. Now at a Bargain Price, Analyst Says (11/29/2022)
Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.
Major Contract and Faster Commercialization for Chemicals Co. (11/29/2022)
Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile.
Expert Says Health Tech Co. Still in Good Spot To Buy (11/28/2022)
Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy.
Biopharma Co. Trades to New 52-Week High (11/28/2022)
Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints in the Phase 3 ACCORD Alzheimer's disease agitation trial.
Pharma Co. Gains Approval for SARS-CoV-2 Drug (11/23/2022)
Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection.
Life Sciences Co. Exceeds Expectations in Q3/22 (11/22/2022)
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.
Q4/22 Catalysts Could Boost Undervalued Biopharma Stock (11/22/2022)
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.
Global Drug Co. Offers US$1.35B To Boost Hematology Assets (11/22/2022)
Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share.
Blockchain Co. Signs Agreement With Insurance Co. (11/22/2022)
Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry.
FDA Awards Breakthrough Therapy Status for AMD Drug (11/21/2022)
Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration.
Pharma Co. Won't See Bump in Sales From New COVID Drug (11/18/2022)
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.
Biopharma Co. Hopes To Turn US$30M Into US$2B (11/17/2022)
CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types.
Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data (11/16/2022)
4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration.
Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment (11/14/2022)
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.
UK Co. Buys NARCAN® Nasal Spray Maker (11/14/2022)
Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met.
US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says (11/11/2022)
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.
Biologics Co. Doubles Revenue in Q3/22 (11/11/2022)
ADMA Biologics Inc. shares traded 27.5% higher yesterday after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million.
Pharma Co. Trades 200% Higher (11/10/2022)
Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma.
Medical Device Co.'s Q2/22 Results Better Than Expected (11/09/2022)
Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America, noted a Research Capital Corp. report.
Nine Stocks Expert Says Should Pique Your Interest (11/09/2022)
Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.
Clean Nuclear Med Tech With Quantum Blue Sky (11/09/2022)
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.
Healthcare Firm Offers US$295M for Ophthalmology Co. (11/08/2022)
Shares of Oyster Point Pharma Inc. traded 38.5% higher yesterday after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share.
Pharma Co. Signs Global License Deal for Eye Drops (11/08/2022)
Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances.
Organ Transplant Co.'s Q3 Revenues Rise 378% (11/04/2022)
Shares of medical technology firm TransMedics Group Inc. traded 24% higher to a new 52-week high after the company reported Q3/22 financial results highlighting a 378% YoY increase in net revenue and raised its FY/22 revenue estimates to US$80-85 million.
Telemedicine Co. Surges on Revenue News (11/04/2022)
As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar.
San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines (11/03/2022)
Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide.
Pharma Co. Earns Big Rewards from Global License Deal (11/02/2022)
Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue.
Biopharma Co. Trades 39% Higher (11/01/2022)
Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant.
More Archives
2024Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
